Experimental results from breast, lung, gastric, liver, hematological, and melanoma models suggest that dysregulated PDK1 signaling can increase the output of the PI3K-AKT-mTOR pathway, invasion, metabolic adaptation, and resistance to specific hormonal, chemotherapeutic, and targeted therapies.
Darshana Ballagere Honnasiddappa, M. Ramar, Tincy Biju et al.· International Journal of Bio...· 0 citations
The results suggest that β-sitosterol acts on multiple targets in breast cancer and identify PGR, a target not strongly favored by docking alone, as an important therapeutic target revealed through extended molecular dynamics simulation.
Alma Khan, Srinivas Ganjipete, Prabu Kumar Seetharaman et al.· Comput. Biol. Chem.· 0 citations
Findings support the hypothesis that ICA may serve as a valuable natural compound for treating HER2‐driven breast cancer; it requires further experimental validation.
